scholarly journals Ulcerative colitis: A review on drug delivery strategies

2020 ◽  
Vol 20 (1) ◽  
pp. 1-15
Author(s):  
El Bethel Lalthavel Hmar ◽  
Sujata Paul ◽  
James H. Zothantluanga ◽  
Hemanta Kumar Sharma
Keyword(s):  
Ulcerative Colitis ◽  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Clinical Course ◽  
Immunosuppressive Drugs ◽  
Oral Route ◽  
Systemic Adverse Effect ◽  
Inflammatory Bowel ◽  
Delivery Strategies ◽  
Upper Gastrointestinal

Ulcerative colitis is one of the two major forms of inflammatory bowel disease which has unforeseeable clinical course, marked by a chronic inflammation of the colon and remission of the disease. The treatment of Ulcerative colitis is managed by the administration of anti-inflammatory or immunosuppressive drugs that are ingested orally. However, the efficacy of the drug via oral route remains unclear as the release of drugs takes place in the upper gastrointestinal tract that allows inadequate amount of drug release to the colon thereby causing various adverse effects. Therefore, the advancement of disease targeted drug delivery strategies offers numerous gains over non-targeting by granting more effective therapy and diminishing the systemic adverse effect. In this review, we investigate and discuss various approaches that assist in targeting mechanism of the respective drugs to the colon for the hindrance and management of colonic ailments.

Nanoparticle-Mediated Therapeutic Approach for Ulcerative Colitis Treatment

2021 ◽  
pp. 96-117
Author(s):  
Subhamoy Banerjee
Keyword(s):  
Ulcerative Colitis ◽  
Drug Delivery ◽  
Polymeric Nanoparticles ◽  
Oral Route ◽  
Alternative Methods ◽  
Active Components ◽  
Life Threatening ◽  
Ulcerative Colitis Treatment ◽  
Inflammatory Bowel ◽  
Bioactive Agents

Ulcerative colitis is a chronic inflammation of the inner part of the colonic mucosa. It is a type of inflammatory bowel disease which is idiopathic in nature. It is multifactorial, debilitating disorder which may cause life threatening complications. Given to the architecture of colon, conventional medicines have limitation in treating the disease. Thus, the need for alternative methods of drug delivery is important. Nanoparticle is one of the preferred drug delivery system owing to its unique properties. Nanoparticles resist undesired and premature degradation of the drugs, increases bioavailability, and target specificity. Different nanoparticle-based drug delivery systems like metallic, liposome, silica, or polymeric nanoparticles have been designed to administer therapeutic agents through oral route to treat ulcerative colitis. Natural compounds and active components isolated from the plant extracts and other bioactive agents are also delivered by nanoparticle. In the current chapter, nanoparticle-mediated drug and phytochemicals delivery to treat ulcerative colitis are discussed.

scholarly journals Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases

2009 ◽  
Vol 7 (suppl_1) ◽  
Author(s):  
Wiebke Ulbrich ◽  
Alf Lamprecht
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Drug Targeting ◽  
Inflammatory Diseases ◽  
Site Of Action ◽  
Specific Uptake ◽  
Inflammatory Bowel ◽  
Delivery Strategies ◽  
Targeted Drug ◽  
High Doses

Limitations in therapy induced by adverse effects due to unselective drug availability and therefore the use of potentially too high doses are a common problem. One prominent example for this dilemma are inflammatory diseases. Colloidal carriers allow one to improve delivery of drugs to the site of action and appear promising to overcome this general therapeutic drawback. Specific uptake of nanoparticles by immune-related cells in inflamed barriers offers selective drug targeting to the inflamed tissue. Here we focus on nanocarrier-based drug delivery strategies for the treatment of common inflammatory disorders like rheumatoid arthritis, multiple sclerosis, uveitis or inflammatory bowel disease.

scholarly journals Recent Advances in Nanoparticle-Mediated Treatment of Inflammatory Bowel Diseases

2021 ◽  
Vol 11 (1) ◽  
pp. 438
Author(s):  
Andreea Nedelcu ◽  
Ofelia Mosteanu ◽  
Teodora Pop ◽  
Teodora Mocan ◽  
Lucian Mocan
Keyword(s):  
Ulcerative Colitis ◽  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Drug Therapy ◽  
Immune Responses ◽  
Biomedical Engineering ◽  
Target Therapy ◽  
Incidence Rates ◽  
Bowel Diseases ◽  
Inflammatory Bowel

There have been continuous advances in nanoscience since the beginning of the 21st century, and the emerging field of computational nanomedicine, the development of nanomaterial-based sensors or the prominent biomedical engineering applications should be mentioned. Intestinal disorders causing prolonged inflammation of the digestive tract, largely known as inflammatory bowel disease (IBD), include Crohn’s disease (CD) and ulcerative colitis (UC), have seen a significant increase in incidence rates. Nanoparticle-based approaches to locally target therapy could help regulate immune responses and act as an anti-inflammatory in individual patients diagnosed with IBD. The results of the paper emphasize the major role that nanoparticle-mediated drug delivery has in IBD treatment, giving IBD patients in remission the chance for a more effective drug therapy with a decreased medication load.

scholarly journals FACTORS ASSOCIATED WITH PATIENT´S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL

2020 ◽  
Vol 57 (4) ◽  
pp. 491-497
Author(s):  
Adhan Amenomori WU ◽  
Jaqueline Ribeiro de BARROS ◽  
Madhoor RAMDEEN ◽  
Julio Pinheiro BAIMA ◽  
Rogerio SAAD-HOSSNE ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapy ◽  
Oral Route ◽  
New Drugs ◽  
Cross Sectional ◽  
Mode Of Administration ◽  
Mode Of Application ◽  
Inflammatory Bowel

BACKGROUND: Biological therapy and new drugs have revolutionized the treatment of inflammatory bowel disease. Ideally, the choice of medication should be a shared decision with the patient, aiming at greater satisfaction, compliance, and consequently, favorable clinical outcome. OBJECTIVE: This study aims to evaluate patient’s preferences in the choice of their therapy and the factors that influence this choice. METHODS: This cross-sectional study enrolled 101 outpatients with Crohn’s disease or ulcerative colitis. The inclusion criteria were age ≥18 years and no previous exposure to biological therapy. Patients’ preferences were assessed through questions that addressed the preferred mode of administration (oral, subcutaneous, or intravenous) and the factors that determined the choice of medication (efficacy, medical indication, fear of medication, convenience, mode of application, and personal doctors’ indication). RESULTS: The mean age was 43.6±13.5 years, 75.3% were female, and 81.2% were cases of ulcerative colitis. Regarding the mode of administration, the majority of patients preferred oral (87.1%), followed by intravenous (6.93%) and subcutaneous (5.94%) medications. The reasons were “I prefer to take it at home” (42.57%), “I have more freedom” (36.63%), “I don’t like self-application” (29.70%), and “I believe it works better” (19.80%). Younger patients and patients in clinical disease activity preferred intravenous mode compared to the oral route (P<0.05). Doctor’s opinion (98%) was an important factor associated with the medication choice. CONCLUSION: Oral route was the preferred mode of administration and most patients took their physician’s opinion into account in their choice of medication.

scholarly journals Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases

2020 ◽  
pp. 1-17
Author(s):  
Emrullah Korkmaz ◽  
Stephen C. Balmert ◽  
Cara Donahue Carey ◽  
Geza Erdos ◽  
Louis D. Falo
Keyword(s):  
Drug Delivery ◽  
Infectious Diseases ◽  
Targeted Drug Delivery ◽  
Delivery Strategies ◽  
Targeted Drug

scholarly journals Overview of 5-ASA in Therapy of Inflammatory Bowel Disease

1994 ◽  
Vol 8 (6) ◽  
pp. 379-382 ◽  
Author(s):  
CN Williams
Keyword(s):  
Ulcerative Colitis ◽  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Side Effects ◽  
Bowel Disease ◽  
Therapeutic Benefit ◽  
Effective Dosage ◽  
Free Oxygen Radicals ◽  
Aminosalicylic Acid ◽  
Inflammatory Bowel

There are two forms of 5-aminosalicylic acid (5-ASA) drug delivery. First, a pro-drug form in which 5-ASA, the active principal, is attached to a c.arrier molecule and released in the intestine by bacterial cleavage. An example of this is sulfasalazine, originally developed in the 1940s and found to be effective, cheap, but limited by side effects due to the sulfapyridine component. The second drug delivery system depends on an enteric coating for delayed pH-dependent release or for a timed-released mechanism. 5-ASA inhibits 5-lipoxygenase, modulates leukocyte function and inhibits soluble mediator release, and is an effective scavenger action of free oxygen radicals, the relative importance of which is unknown. The multiplicity of action is probably its strength because drugs that have only one of these actions are relatively ineffective in inflammatory bowel disease. 5-ASA compounds are effective in treating mild to moderate acute ulcerative colitis and in maintaining remission, and are equivalent to sulfasalazine in this regard. 5-ASA used topically in enema or suppository form is highly efficient in both acute disease and in maintaining remission. 5-ASA is also effective in active Crohn’s disease, but not as effective as in maintenance therapy compared with ulcerative colitis. The pro-drugs tend to have more side effects. Slow release compounds are well tolerated with few side effects, allowing increases to effective dosage. In patients intolerant of sulfasalazine, switching to a 5-ASA preparation usually results in tolerance and therapeutic benefit, with an occasional allergic reaction to the 5-ASA molecule limiting its use.

Sign in / Sign up

Export Citation Format

Share Document